Diality names Peter Donato as chief financial officer

Diality Inc., a medical device company developing hemodialysis systems, appointed Peter Donato as chief financial officer. The company announced the appointment as it continues patient enrollment in its PRESCRIBE Diality Home Hemodialysis Clinical Trial and prepares for a limited market release in 2027.

Donato brings nearly 35 years of financial leadership experience, including over 23 years in life sciences companies. He previously served as CFO of heart failure device company Impulse Dynamics and chief financial and administrative officer of companion pet health company Zomedica (NYSE: ZOM). He also held executive positions at Standard Bariatrics, which was sold to Teleflex (NYSE: TFX) for approximately $300 million in 2022, and led the IPO of Neuronetics (NASDAQ: STIM) in 2018.

His prior experience includes roles at Assurex Health, which was sold to Myriad (NASDAQ: MYGN) for $410 million in 2016, Bovie Medical, Cyberonics, and Iris International.

"Peter joins Diality at a pivotal time, as we prepare for the commercialization of Moda-flx to help more nephrologists and care teams improve the daily living of dialysis patients," said CEO Osman Khawar.

Diality's Moda-flx Hemodialysis System received FDA clearance for use in professional care settings in August 2024. The system features variable flow rates, integrated water filtration, and a graphical user interface designed for clinical flexibility in hemodialysis treatment.

The information is based on a company press release.

You May Also Be Interested In

• Biohaven names new discovery head as CSO shifts to part-time role
• AutoZone promotes Grace Sharpley to SVP of Finance
• Ategrity reports record Q2 results, names new CFO